DEPARTMENT OF FISH AND GAME

Carolyn S. Friedman, PhD c/o Bodega Marine Laboratory P.O. Box 247
Bodega Bay, 'California 94923 707/875-2067
email: csfriedman@ucdavis.edu

5695 '99 NOV 24 P3:35



RE: CPG "Use of Medicated Feeds for Minor Species" 99D-2638
Section 615.115

To Whom it May Concern,

I have reviewed the draft CPG for extra-label use of therapeutant in minor species. My concern focuses on cultured marine and freshwater fish and invertebrates, species for which few therapeutants are approved. Due to the paucity of drugs that are legally available for use in cultured aquatic and marine species, the ability of qualified veterinarians. to prescribe 'extra-label therapeutants is crucial for humane treatment of the animals and the success of the aquaculture industry. In addition, due to the size, number, physiology and stress susceptibility of aquatic and marine animals, administration of a therapeutant is typically only feasible as a oral application. This fact, in conjunction with the docket 99D-2638, suggests that the act of prescribing a therapeutant by a licensed veterinarian and/or the application of a therapeutant by a culturist is an illegal act. That the FDA "will not ordinarily consider regulatory action against the veterinarian or animal producer provided all of the circumstances listed below exist" does not provide adequate assurance to the fish/invertebrate veterinarians or culturists who are acting in the best interest of the fish or invertebrate by treating a disease. This will result in a hesitance of veterinarians to establish relationships with and provide service to the fish/shellfish culture industries which, in turn, will result in a reduction in the ability of aquaculturists to maintain a high quality of animal husbandry during a disease epizootic. As the shellfish pathologist of the California Department of Fish & Game and a scientist who studies diseases of marine shellfish and works closely with the aquaculture industry. I firmly believe that an exception to the current regulatory status for extra-label prescription of therapeutants in feed for cultured marine and freshwater animals is warranted. My suggestion is that the aquaculture community and its veterinarians should be able, to, use and prescribe o&label therapeutants in feed as long as the requirements in Section 615.115 are met. Thus, this only necessitates a change of status for these species, not the proper requirements of client/patient relationship, withdrawal times, etc.

Please let me, know if you have any questions. I would appreciate a response to this letter.

Sincerely,

Carolyn S. Friedman, PhD Senior Fish Pathologist

990-2638

C11

og kombûre û regelîz ji dir ku ji birê. Dire birê dire dire dika ku zîrêtê

n i de grecieda de congecção do com

UNIVERSITY OF CALIFORNIA BODEGA MARINE LABORATORY P.O. BOX 247 BODEGA BAY, CALIFORNIA 94923



Dockets Management Branch (HFA-305)
Food + Drug Administration
5630 Fishers Lane, (In 1061
Rockville, MD 20852